DUBLIN–(BUSINESS WIRE)–The “Leber’s Hereditary Optic Neuropathy (Leber optic atrophy) – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The Publisher’s Pharmaceutical and Healthcare latest pipeline guide Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 2, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively.
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Overview
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Therapeutics Development
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Therapeutics Assessment
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Companies Involved in Therapeutics Development
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drug Profiles
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Dormant Projects
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Product Development Milestones
Appendix
Companies Mentioned
- Alkeus Pharmaceuticals Inc
- Antoxis Ltd
- Biovista Inc
- Fortify Therapeutics Inc
- GenSight Biologics SA
- Ixchel Pharma LLC
- Khondrion BV
- Metro International Biotech LLC
- Mitobridge Inc
- Mitotech SA
- Nanna Therapeutics Ltd
- Neuroptika Inc
- Santhera Pharmaceuticals Holding AG
- Spark Therapeutics Inc
- Stealth BioTherapeutics Corp
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hp1wmj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900